Cáncer Mamario

Volver al artículo.

Referencias para el artículo

  1. Smith-Warner SA, Spiegelman D, Yaun SS, et al. Alcohol and breast cancer in women. A pooled analysis of cohort studies. JAMA 1998;279:535–40.
  2. Garland M, Hunter DJ, Colditz GA, et al. Alcohol consumption in relation to breast cancer risk in a cohort of United States women 25–42 years of age. Cancer Epidemiol Biomarkers Prev 1999;8:1017–21.
  3. Purohit V. Moderate alcohol consumption and estrogen levels in postmenopausal women: a review. Alcohol Clin Exp Res 1998;22:994–7.
  4. Ginsburg ES, Mello NK, Mendelson JH, et al. Effects of alcohol ingestion on estrogens in postmenopausal women. JAMA 1996;276:1747–51.
  5. Becker U, Gluud C, Bennet P, et al. Effect of alcohol and glucose infusion on pituitary-gonadal hormones in normal females. Drug Alcohol Depend 1988;22:141–9.
  6. Zhang S, Hunter DJ, Hankinson SE, et al. A prospective study of folate intake and the risk of breast cancer. JAMA 1999;281:1632–7.
  7. Zhang S, Hunter DJ, Hankinson SE, et al. A prospective study of folate intake and the risk of breast cancer. JAMA 1999;281:1632–7.
  8. Rao GN, Ney E, Herbert RA. Influence of diet on mammary cancer in transgenic mice bearing an oncogene expressed in mammary tissue. Breast Cancer Res Treat 1997;45:149–58.
  9. Jacobs DR Jr, Marquart L, Salvin J, Kushi LH. Whole-grain intake and cancer: an expanded review and meta-analysis. Nutr Cancer 1998;30:85–96.
  10. La Vecchia C, Ferraroni M, Franceschi S, et al. Fibers and breast cancer risk. Nutr Cancer 1997;28:264–9.
  11. Golden BR, Woods MN, Spiegelman DL, et al. The effect of dietary fat and fiber on serum estrogen concentrations in premenopausal women under controlled dietary conditions. Cancer 1994;74(3 Suppl):1125–31.
  12. Stark AH, Switzer BR, Atwood JR, et al. Estrogen profiles in postmenopausal African-American women in a wheat bran fiber intervention study. Nutr Cancer 1998;31:138–42.
  13. Baghurst PA, Rohan TE. High-fiber diets and reduced risk of breast cancer. Int J Cancer 1994;56:173–6.
  14. Cohen LA. Dietary fiber and breast cancer. Anticancer Res 1999;19:3685–8.
  15. Frentzel-Beyme R, Chang-Claude J. Vegetarian diets and colon cancer: the German experience. Am J Clin Nutr 1994;59(suppl):1143–52S.
  16. Kinlen LJ, Hermon C, Smith PG. A proportionate study of cancer mortality among members of a vegetarian society. Br J Cancer 1983;48:355–61.
  17. Malter M, Schriever G, Eilber U. Natural killer cells, vitamins, and other blood components of vegetarian and omnivorous men. Nutr Cancer 1989;32:271–8.
  18. Armstrong BK, Brown JB, Clarke HT, et al. Diet and reproductive hormones: a study of vegetarian and nonvegetarian postmenopausal women. J Natl Cancer Inst 1981:67:761–7.
  19. Gandini S, Merzenich H, Robertson C, Boyle P. Meta-analysis of studies on breast cancer risk and diet: the role of fruit and vegetable consumption and the intake of associated micronutrients. Eur J Cancer 2000;36:636–46.
  20. Smith-Warner SA, Spiegelman D, Yaun SS, et al. Intake of fruits and vegetables and risk of breast cancer. A polled analysis of cohort studies. JAMA 2001;285:769–76.
  21. Smith-Warner SA, Spiegelman D, Yaun SS, et al. Intake of fruits and vegetables and risk of breast cancer. A polled analysis of cohort studies. JAMA 2001;285:769–76.
  22. Levy J, Bosin E, Feldman B, et al. Lycopene is a more potent inhibitor of human cancer cell proliferation than either α-carotene or β-carotene. Nutr Cancer 1995;24:257–66.
  23. Giovannucci E. Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J Natl Cancer Inst 1999;91:317–31.
  24. Zheng W, Gustafson DR, Sinha R, et al. Well-done meat intake and the risk of breast cancer. J Natl Cancer Inst 1998;90:1724–9.
  25. De Stefani E, Ronco A, Mendilaharsu M, et al. Meat intake, heterocyclic amines, and risk of breast cancer : a case-control study in Uruguay. Cancer Epidemiol Biomarkers Prev 1997;6:573–81.
  26. Ambrosone CB, Freudenheim JL, Sinha R, et al. Breast cancer risk, meat consumption and N-acetyltransferase (NAT2) genetic polymorphisms. Int J Cancer 1998;75:825–30.
  27. Bjeldanes LF, Morris MM, Felton JS, et al. Effect of meat composition and cooking conditions on mutagen formation in fried ground beef. J Agriculture Food Chem 1983;31:18–21.
  28. Zheng W, Gustafson DR, Sinha R, et al. Well-done meat intake and the risk of breast cancer. J Natl Cancer Inst 1998;90:1724–9.
  29. Zheng W, Deitz AC, Campbell DR, et al. N-acetyltransferase 1 genetic polymorphism, cigarette smoking, well-done meat intake, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999;8:233–9.
  30. Kaizer L, Boyd NF, Kriukov V, Tritchler D. Fish consumption and breast cancer risk: an ecological study. Nutr Cancer 1989;12:61–8.
  31. Rose DP, Connolley JM. Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol Ther 1999;83:217–44.
  32. Dixon JM, McDonald C, Elton RA, et al. Risk of breast cancer in women with palpable breast cysts : a prospective study. Lancet 1999;353:1742–5.
  33. Tavani A, Pregnolato A, La Vecchia C, et al. Coffee consumption and the risk of breast cancer. Eur J Cancer Prev 1998;7:77–82.
  34. Lubin F, Ron E, Wax Y, Modan B. Coffee and methylxanthines and breast cancer: a case-control study. J Natl Cancer Inst 1985;74:569–73.
  35. Rosenberg L, Miller DR, Helmrich SP, et al. Breast cancer and the consumption of coffee. Am J Epidemiol 1985;122:391–9.
  36. Trichopoulou A, Katsouyanni K, Stuver S, et al. Consumption of olive and specific food groups in relation to breast cancer risk in Greece. J Natl Cancer Inst 1995;87:110–6.
  37. La Vecchia C, Negri E, Franceschi S, et al. Olive oil, other dietary fats, and the risk of breast cancer (Italy). Cancer Causes Control 1995;6:545–50.
  38. Martin-Moreno JM, Willett WC, Gorgojo L, et al. Dietary fat, olive oil intake and breast cancer risk. Int J Cancer 1994;58:774–80.
  39. Shun-Zhang Y, Rui-Fang L, Da-Dao X, Howe GR. A case-control study of dietary and nondietary risk factors for breast cancer in Shanghai. Cancer Res 1990;50:5017–21.
  40. Simonsen NR, Navajas JF-C, Martin-Moreno JM, et al. Tissue stores of individual monounsaturated fatty acids and breast cancer: the EURAMIC study. Am J Clin Nutr 1998;68:134–41.
  41. Trichopoulou A, Katsouyanni K, Stuver S, et al. Consumption of olive and specific food groups in relation to breast cancer risk in Greece. J Natl Cancer Inst 1995;87:110–6.
  42. La Vecchia C, Negri E, Franceschi S, et al. Olive oil, other dietary fats, and the risk of breast cancer (Italy). Cancer Causes Control 1995;6:545–50.
  43. Martin-Moreno JM, Willett WC, Gorgojo L, et al. Dietary fat, olive oil intake and breast cancer risk. Int J Cancer 1994;58:774–80.
  44. Kaizer L, Boyd NF, Kriukov V, Tritchler D. Fish consumption and breast cancer risk: an ecological study. Nutr Cancer 1989;12:61–8.
  45. Fay MP, Freedman LS, Clifford CK, Midthune DN. Effect of different types and amounts of fat on the development of mammary tumors in rodents: a review. Cancer Res 1997;57:3979–88.
  46. Armstrong B, Doll R. Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer 1975;15:617–31.
  47. Boyar AP, Rose DP, Loughridge JR, et al. Response to a diet low in total fat in women with postmenopausal breast cancer: a pilot study. Nutr Cancer 1988;11:93–9.
  48. Bagga D, Ashley JM, Geffrey SP, et al. Effects of a very low fat, high fiber diet on serum hormones and menstrual function. Cancer 1995;76:2491–6.
  49. Chlebowski RT, Blackburn GL, Buzzard IM, et al. Adherence to a dietary fat intake reduction program in postmenopausal women receiving therapy for early breast cancer. J Clin Oncol 1993;11:2072–80.
  50. Boyd NF, Greenberg C, Lockwood G, et al. Effects at two years of a low-fat, high-carbohydrate diet on radiologic features of the breast: results from a randomized trial. J Natl Cancer Inst1997;89:488–96.
  51. Jain M, Miller AB, To T. Premorbid diet and the prognosis of women with breast cancer. J Natl Cancer Inst 1994;86:1390–7.
  52. Herbert JR, Hurley TG, Ma Yunsheng. The effect of dietary exposures on recurrence and mortality in early stage breast cancer. Breast Cancer Res Treat 1998;51:17–28.
  53. Howe GR, Hirohata T, Hislop G, et al. Dietary factors and risk of breast cancer : combined analysis of 12 case-control studies. J Natl Cancer Inst 19990;82:561–9.
  54. Toniolo P, Riboli E, Protta F, et al. Calorie-providing nutrients and risk of breast cancer. J Natl Cancer Inst 1989;81:278–6.
  55. Holmes MD, Hunter DH, Colditz GA, et al. Association of dietary intake of fat and fatty acids with risk of breast cancer. JAMA 1999;281:914–20.
  56. Jones DY, Schatzkin A, Green SB, et al. Dietary fat and breast cancer in the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. J Natl Cancer Inst 1987;79:465–71.
  57. Newman SC, Miller AB, Howe GR. A study of the effect of weight and dietary fat on breast cancer survival time. Am J Epidemiol 1986;123:767–74.
  58. Howe GR, Friedenreich CM, Jain M, Miller AB. A cohort study of fat intake and risk of breast cancer. J Natl Cancer Inst 1991;83:336–40.
  59. Trichopoulou A, Katsouyanni K, Stuver S, et al. Consumption of olive and specific food groups in relation to breast cancer risk in Greece. J Natl Cancer Inst 1995;87:110–6.
  60. La Vecchia C, Negri E, Franceschi S, et al. Olive oil, other dietary fats, and the risk of breast cancer (Italy). Cancer Causes Control 1995;6:545–50.
  61. Martin-Moreno JM, Willett WC, Gorgojo L, et al. Dietary fat, olive oil intake and breast cancer risk. Int J Cancer 1994;58:774–80.
  62. Kaizer L, Boyd NF, Kriukov V, Tritchler D. Fish consumption and breast cancer risk: an ecological study. Nutr Cancer 1989;12:61–8.
  63. Jones DY, Schatzkin A, Green SB, et al. Dietary fat and breast cancer in the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. J Natl Cancer Inst 1987;79:465–71.
  64. Newman SC, Miller AB, Howe GR. A study of the effect of weight and dietary fat on breast cancer survival time. Am J Epidemiol 1986;123:767–74.
  65. Saskai S, Moracsek M, Kesteloot H. An ecological study of the relationship between dietary fat intake and breast cancer mortality. Prev Med 1993;22:187–202.
  66. Armstrong B, Doll R. Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer 1975;15:617–31.
  67. Wu AH, Ziegler RG, Nomura AMY, et al. Soy intake and risk of breast cancer in Asians and Asian Americans. Am J Clin Nutr 1998;68(suppl):1437–43S [review].
  68. Wu AH, Ziegler RG, Horn-Ross PL, et al. Tofu and risk of breast cancer in Asian-Americans. Cancer Epidemiol Biomarkers Prev 1996;5:901–6.
  69. Messina MJ, Persky V, Setchell KDR, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 1994;21:113–31 [review].
  70. Messina MJ. Legumes and soybeans: overview of their nutritional profiles and health effects. Am J Clin Nutr 1999;70(suppl):439–50S [review].
  71. Barnes S. The chemopreventive properties of soy isoflavonoids in animal models of breast cancer. Breast Cancer Res Treat 1997;46:169–79 [review].
  72. Hilakivi-Clarke L, Cho E, Onojafe I, et al. Maternal exposure to genistein during pregnancy increases carcinogen-induced mammary tumorigenesis in female rat offspring. Oncol Rep 1999;6:1089–95.
  73. Hargreaves DNF, Potten CS, Harding C, et al. Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocrinol Metab 1999;84:4017–24.
  74. Petrakis NL, Barnes S, King EB, et al. Stimulatory influence of soy protein isolate on breast secretion in pre- and postmenopausal women. Cancer Epidemiol Biomarkers Prev 1996;5:785–94.
  75. McMichael-Phillips DF, Harding C, Morton M, et al. Effects of soy-protein supplementation on epithelial proliferation in the histologically normal human breast. Am J Clin Nutr 1998;68(suppl):1431–6S.
  76. Barnes S. The chemopreventive properties of soy isoflavonoids in animal models of breast cancer. Breast Cancer Res Treat 1997;46:169–79 [review].
  77. Hilakivi-Clarke L, Cho E, Onojafe I, et al. Maternal exposure to genistein during pregnancy increases carcinogen-induced mammary tumorigenesis in female rat offspring. Oncol Rep 1999;6:1089–95.
  78. Lu LJ, Anderson KE, Grady JJ, Nagamani M. Effects of soya consumption for one month on steroid hormones in premenopausal women: implications for breast cancer risk reduction. Cancer Epidemiol Biomarkers Prev 1996;5:63–70.
  79. Nagato C, Takatsuka N, Inaba S, et al. Effect of soymilk consumption on serum estrogen concentrations in premenopausal Japanese women. J Natl Cancer Inst 1998;90:1830–5.
  80. Hargreaves DNF, Potten CS, Harding C, et al. Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocrinol Metab 1999;84:4017–24.
  81. Petrakis NL, Barnes S, King EB, et al. Stimulatory influence of soy protein isolate on breast secretion in pre- and postmenopausal women. Cancer Epidemiol Biomarkers Prev 1996;5:785–94.
  82. McMichael-Phillips DF, Harding C, Morton M, et al. Effects of soy-protein supplementation on epithelial proliferation in the histologically normal human breast. Am J Clin Nutr 1998;68(suppl):1431–6S.
  83. Barnes S. The chemopreventive properties of soy isoflavonoids in animal models of breast cancer. Breast Cancer Res Treat 1997;46:169–79 [review].
  84. Hilakivi-Clarke L, Cho E, Onojafe I, et al. Maternal exposure to genistein during pregnancy increases carcinogen-induced mammary tumorigenesis in female rat offspring. Oncol Rep 1999;6:1089–95.
  85. Hargreaves DNF, Potten CS, Harding C, et al. Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocrinol Metab 1999;84:4017–24.
  86. Petrakis NL, Barnes S, King EB, et al. Stimulatory influence of soy protein isolate on breast secretion in pre- and postmenopausal women. Cancer Epidemiol Biomarkers Prev 1996;5:785–94.
  87. McMichael-Phillips DF, Harding C, Morton M, et al. Effects of soy-protein supplementation on epithelial proliferation in the histologically normal human breast. Am J Clin Nutr 1998;68(suppl):1431–6S.
  88. Messina MJ. Legumes and soybeans: overview of their nutritional profiles and health effects. Am J Clin Nutr 1999;70(suppl):439–50S [review].
  89. Barnes S. The chemopreventive properties of soy isoflavonoids in animal models of breast cancer. Breast Cancer Res Treat 1997;46:169–79 [review].
  90. Hilakivi-Clarke L, Cho E, Onojafe I, et al. Maternal exposure to genistein during pregnancy increases carcinogen-induced mammary tumorigenesis in female rat offspring. Oncol Rep 1999;6:1089–95.
  91. Hargreaves DNF, Potten CS, Harding C, et al. Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocrinol Metab 1999;84:4017–24.
  92. Petrakis NL, Barnes S, King EB, et al. Stimulatory influence of soy protein isolate on breast secretion in pre- and postmenopausal women. Cancer Epidemiol Biomarkers Prev 1996;5:785–94.
  93. McMichael-Phillips DF, Harding C, Morton M, et al. Effects of soy-protein supplementation on epithelial proliferation in the histologically normal human breast. Am J Clin Nutr 1998;68(suppl):1431–6S.
  94. Messina M, Barnes S. The role of soy products in reducing risk of cancer. J Natl Cancer Inst 1991;83:541–6 [review].
  95. Burley VJ. Sugar consumption and human cancer in sites other than the digestive tract. Eur J Cancer Prev 1998;7:253–77 [review].
  96. Decarli A, Favero A, La Vecchia C, et al. Macronutrients, energy intake, and breast cancer risk: implications from different models. Epidemiology 1997;8:425–8.
  97. Marcus PM, Newman B, Moorman PG, et al. Physical activity at age 12 and adult breast cancer risk (United States). Cancer Causes Control 1999;10:293–302.
  98. Bullen BA, Skrinar GS, Beitins IZ, et al. Induction of menstrual disorders by strenuous exercise in untrained women. N Engl J Med 1985;312:1349–53.
  99. Rockhill B, Willett WC, Hunter DJ, et al. A prospective study of recreational physical activity and breast cancer risk. Arch Intern Med 1999;159:2290–6.
  100. Thune I, Brenn T, Lund E, Gaard M. Physical activity and the risk of breast cancer. N Engl J Med 1997;336:1269–75.
  101. Gammon MD, Schoenberg JB, Britton JA, et al. Recreational physical activity and breast cancer risk among women under age 45 years. Am J Epidemiol 1998;147:273–80.
  102. Gram IT, Funkhouser E, Tabar L. Moderate physical activity in relation to mammographic patterns. Cancer Epidemiol Biomarkers Prev 1999;8:117–22.
  103. Segar ML, Katch VL, Roth RS, et al. The effect of aerobic exercise on self-esteem and depressive and anxiety symptoms among breast cancer survivors. Oncol Nurs Forum 1998;25:107–13.
  104. Johnson KC, Hu J, Mao Y, & The Canadian Cancer Registries Epidemiology Research Group. Passive and active smoking and breast cancer risk in Canada, 1994–7. Cancer Causes Control 2000;11:211–21.
  105. London SJ, Colditz GA, Stampfer JM, et al. Prospective study of smoking and the risk of breast cancer. J Natl Cancer Inst 1989;81:1625–31.
  106. Gammon MD, Schoenberg JB, Teitelbaum SL, et al. Cigarette smoking and breast cancer risk among young women (United States). Cancer Causes Control 1998;9:583–90.
  107. Lash TJ, Aschengrau A. Active and passive cigarette smoking and the occurrence of breast cancer. Am J Epidemiol 1999;149:5–12.
  108. Gallo JJ, Armenian HK, Ford DE. Major depression and cancer: the 13-year follow-up of the Baltimore Epidemiologic Catchment Area sample (United States). Cancer Causes Control 2000;11:751–8.
  109. Chen CC, David AS, Nunnerley H, et al. Adverse life events and breast cancer: case-control study. BMJ 1995;311:1527–30.
  110. Geyer S. Life events prior to manifestation of breast cancer: a limited prospective study covering eight years before diagnosis. J Psychosomatic Res 1991;35:355–63.
  111. Protheroe D, Turvey K, Horgan K, et al. Stressful life events and difficulties and onset of breast cancer: case-control study. BMJ 1999;319:1027–30.
  112. Ramirez AJ, Craig TK, Watson JP, et al. Stress and relapse of breast cancer. BMJ 1989;298:291–3.
  113. Roberts FD, Newcomb PA, Trentham-Dietz A, Storer BE. Self-reported stress and risk of breast cancer. Cancer 1996;77:1089–93.
  114. Barraclough J, Pinder P, Cruddas M, et al. Life events and breast cancer prognosis. BMJ 1992;304:1078–81.
  115. Tross S, Herndon J II, Korzun A, et al. Psychological symptoms and disease-free and overall survival in women with stage II breast cancer. J Natl Cancer Inst 1996;88:661–7.
  116. Andersen BL, Farrar WB, Golden-Kreutz D, et al. Stress and immune response after surgical treatment for regional breast cancer. J Natl Cancer Inst 1998;90:30–6.
  117. Levy SM, Herberman RB, Whiteside T, et al. Perceived social support and tumor estrogen/progesterone receptor status as predictors of natural killer cell activity in breast cancer patients. Psychosomatic Med 1990;52:73–85.
  118. Andersen BL, Farrar WB, Golden-Kreutz D, et al. Stress and immune response after surgical treatment for regional breast cancer. J Natl Cancer Inst 1998;90:30–6.
  119. Levy SM, Herberman RB, Whiteside T, et al. Perceived social support and tumor estrogen/progesterone receptor status as predictors of natural killer cell activity in breast cancer patients. Psychosomatic Med 1990;52:73–85.
  120. Mausell E, Brisson J, Deschênes L. Social support and survival among women with breast cancer. Cancer 1995;76:631–7.
  121. Pettingall KW, Morris T, Greer S, Haybittle JL. Mental attitudes to cancer: an additional prognostic factor. Lancet 1985;i:750.
  122. Greer S, Morris T, Pettingale KW, Haybittle JL. Psychological response to breast cancer and 15-year outcome. Lancet 1990;335:49–50 [letter].
  123. Watson M, Haviland JS, Greer S, et all. Influence of psychological response on survival in breast cancer: a population-based cohort study. Lancet 1999;354:1331–6.
  124. Greer S, Moorey S, Baruch JDR, et al. Adjuvant psychological therapy for patients with cancer: a prospective randomised trial. Lancet 1992;304:675–80.
  125. Simonton OC, Matthews-Simonton S. Cancer and stress. Counseling the cancer patients. Med J Aust 1981;1:679–83.
  126. Grossarth-Maticek R, Eysenck HJ. Length of survival and lymphocyte percentage in women with mammary cancer as a function of psychotherapy. Psychol Rep 1989;65:315–21.
  127. Spiegel D, Bloom JR, Kraemer HC, Gottheil. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet 1989;ii:888–91.
  128. Bridge LR, Benson P, Pietroni PC, Priest RG. Relaxation and imagery in the treatment of breast cancer. BMJ 1988;297:1169–72.
  129. Spiegel D, Bloom JR. Group therapy and hypnosis reduce metastatic breast carcinoma pain. Psychosom Med 1983;45:333–9.
  130. Gellert GA, Maxwell RM, Siegel BS. Survival of breast cancer patients receiving adjunctive psychosocial support therapy: a 10-year follow-up study. J Clin Oncol 1993;11:66–9.
  131. Peacock SL, White E, Daling JR, et al. Relation between obesity and breast cancer in young women. Am J Epidmeiol 1999;149:339–46.
  132. Rohan TE, Jain MG, Howe GR, Miller AB. Dietary folate consumption and breast cancer risk. J Natl Cancer Inst 2000;92:266–9.
  133. Zhang S, Hunter DJ, Hankinson SE, et al. A prospective study of folate intake and the risk of breast cancer. JAMA 1999;281:1632–7.
  134. Zhang S, Hunter DJ, Hankinson SE, et al. A prospective study of folate intake and the risk of breast cancer. JAMA 1999;281:1632–7.
  135. Fex G, Pettersson B, Akesson B. Low plasma selenium as a risk factor for cancer death in middle-aged men. Nutr Cancer 1987;10:221–9.
  136. Knekt P, Aromaa A, Maatela J, et al. Serum selenium and subsequent risk of cancer among Finnish men and women. J Natl Cancer Inst 1990;82:864–8.
  137. Kok FJ, deBruijn AM, Hofman A, et al. Is serum selenium a risk factor for cancer in men only? Am J Epidemiol 1987;125:12–6.
  138. Brock KE, Gridley G, Morris JS, Willett WC. Serum selenium level in relation to in situ cervical cancer in Australia. J Natl Cancer Inst 1991;83:292–3.
  139. Knekt P, Aromaa A, Maatela J, et al. Serum selenium and subsequent risk of cancer among Finnish men and women. J Natl Cancer Inst 1990;82:864–8.
  140. Kok FJ, deBruijn AM, Hofman A, et al. Is serum selenium a risk factor for cancer in men only? Am J Epidemiol 1987;125:12–6.
  141. Hunter DJ, Morris JS, Stampfer MJ, et al. A prospective study of selenium status and breast cancer risk. JAMA 1990;264:1128–31.
  142. Helzlsouer KJ, Alberg AJ, Norjus EP, et al. Prospective study of serum micronutrients and ovarian cancer. J Natl Cancer Inst 1996;88:32–7.
  143. Vinceti M, Rovesti S, Gabrielli C, et al. Cancer mortality in a residential cohort exposed to environmental selenium through drinking water. J Clin Epidemiol 1995;48:1091–7.
  144. Garland M, Morris JS, Stampfer MJ, et al. Prospective study of toenail selenium levels and cancer among women. J Natl Cancer Inst 1995;87:497–505.
  145. Clark LC, Alberts DS. Selenium and cancer: risk or protection? J Natl Cancer Inst 1995;87:473–5 [editorial].
  146. Clark LC, Combs GF Jr, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA 1996;276:1957–63.
  147. Clark LC, Combs GF Jr, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA 1996;276:1957–63.
  148. Thompson HJ, Meeker LD, Becci PJ, Kokoska S. Effect of short-term feeding of sodium selenite on 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in the rat. Cancer Res 1982;42:4954–8.
  149. Schrauzer GN, Ishmael D. Effects of selenium and of arsenic on the genesis of spontaneous mammary tumors in inbred C3H mice. Ann Clin Lab Sci 1974;4:441–7.
  150. Schrauzer GN, Molenaar T, Mead S, et al. Selenium in the blood of Japanese and American women with and without breast cancer and fibrocystic disease. Jpn J Cancer Res (Gann) 1985;76:374–7.
  151. McConnell KP, Jager RM, Bland KI, Blotcky AJ. The relationship of dietary selenium and breast cancer. J Surg Oncol 1980;15:67–70.
  152. Hunter DJ, Morris JS, Stampfer MJ, et al. A prospective study of selenium status and breast cancer risk. JAMA 1990;264:1128–31.
  153. Van’t Veer P, van der Wielen RPG, Kok FJ, et al. Selenium in diet, blood, and toenails in relation to breast cancer: a case-control study. Am J Epidemiol 1990;131:987–94.
  154. Van den Brandt PA, Goldbohm A, van’t Veer P, et al. Toenail selenium levels and the risk of breast cancer. Am J Epidemiol 1994;140:20–6.
  155. Van Noord PA, Collette HJ, Maas MJ, de Waard F. Selenium levels in nails of premenopausal breast cancer patients assessed prediagnostically in a cohort-nested case-referent study among women screened in the DOM project. Int J Epidemiol 1987;16:318–22.
  156. Garland M, Willett WC, Manson JE, Hunter DJ. Antioxidant micronutrients and breast cancer. J Am Coll Nutr 1993;12400–11 [review].
  157. Clark LC, Combs GF Jr, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA 1996;276:1957–63.
  158. Männistö S, Alfthan G, Virtanen M, et al. Toenail selenium and breast cancer––a case-control study in Finland. Eur J Clin Nutr 2000;54:98–103.
  159. Torun M, Akgul S, Sargin H. Serum vitamin E level in patients with breast cancer. J Clin Pharmacol Ther 1995;20:173–8.
  160. Wald NJ, Boreham J, Hawward JL, et al. Plasma retinol, ß-carotene and vitamin E levels in relation to the future risk of breast cancer. Br J Cancer 1984;49:321–4.
  161. Kimmick GG, Bell RA, Bostick RM. Vitamin E and breast cancer: a review. Nutr Cancer 1997;27:109–17.
  162. Gerber M, Richardson S, Crastes de Paulet P, et al. Relationship between vitamin E and polyunsaturated fatty acids in breast cancer. Cancer 1989;64:2374–53.
  163. Gerber M, Cavallo F, Marubini E, et al. Liposoluble vitamins and lipid parameters in breast cancer. A joint study in northern Italy and southern France. Int J Cancer 1988;42:489–94.
  164. Hunter DJ, Manson JE, Colditz GA, et al. A prospective study of the intake of vitamins C, E, and A and the risk of breast cancer. N Engl J Med 1993;329:234–40.
  165. Knekt P. Serum vitamin E level and risks of female cancers. Int J Epidemiol 1988;17:281–8.
  166. Pussinen PJ, Lindner H, Glatter O, et al. Lipoprotein-associated alpha-tocopheryl-succinate inhibits cell growth and induces apoptosis in human MCF-7 and HBL-100 breast cancer cells. Biochim Biophys Acta 2000;1485:129–44.
  167. Gorham ED, Garland FC, Garland CF. Sunlight and breast cancer incidence in the USSR. Int J Epidemiol 1990;19:820–4.
  168. Anzano MA, Smith JM, Uskokovic, et al. 1α,25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24–5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat. Cancer Res 1994;54:1653–6.
  169. Demdirpence E, Balaguer P, Trousse F, et al. Antiestrogenic effects of all-trans-retinoic acid and 1,25-dihydroxyvitamin D3 in breast cancer cells occur at the estrogen response element level but through different molecular mechanisms. Cancer Res 1994;54:1458–64.
  170. John EM, Schwartz GG, Dreon DM, Koo J. Vitamin D and breast cancer risk: the NHANES I Epidemiologic follow-up study, 1971–1975 to 1992. Cancer Epidemiol Biomarkers Prev 1999;8:399–406.
  171. Vink-van Wijngaarden T, Pols HA, Buurman CJ, et al. Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen. Cancer Res 1994;54:5711–7.
  172. James SY, Merceer E, Brady M, et al. ERB1089, a synthetic analogue of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro. Br J Pharmacol 1998;125:953–62.
  173. Eisman JA, Barkla DH, Tutton PJM. Suppression of in vitro growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3. Cancer Res 1987;47:21–5.
  174. Ravid A, Rocker D, Machlenkin A, et al. 1,25-dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer Res 1999;59:862–7.
  175. Bower M, Colston KW, Stein RC, et al. Topical calcipotriol treatment in advanced breast cancer. Lancet 1991;337:701–2.
  176. Colston KW, Berger U, Coombes RC. Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet 1989;I:188–91.
  177. Eisman JA, Suva LJ, Martin TJ. Significance of 1,25-dihydroxyvitamin D3 receptor in primary breast cancer. Cancer Res 1986;46:5406–8.
  178. Freake HC, Abeyasekera G, Iwasaki J, et al. Measurement of 1,25-dihydroxyvitamin D3 receptors in breast cancer and their relationship to biochemical and clinical indices. Cancer Res 1984;44:1677–81.
  179. Cos S, Fernández R, Güézmes A, Sánchez-Barceló EJ. Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res 1998;58:4383–90.
  180. Mediavilla MD, Cos S, Sánchez-Barceló EJ. Melatonin increases p53 and p21 WAF1 expression in MCF-7 human breast cancer cells in vitro. Life Sci 1999;65:415–20.
  181. Baldwin WS, Travlos GS, Risinger JI, Barrett JC. Melatonin does not inhibit estradiol-stimulated proliferation in MCF-7 and BG-1 cells. Carcinogenesis 1998;19:1895–1900.
  182. Lissoni P, Barmo S. Meregalli S, et al. Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer 1995;71:854–6.
  183. Neri B, De Leonardis V, Gemelli MT, et al. Melatonin as biological response modifier in cancer patients. Anticancer Res 1998;18:1329–32.
  184. Lissoni P, Barni S, Crispino S, et al. Endocrine and immune effects of melatonin therapy in metastatic cancer patients. Eur J Cancer Clin Oncol 1989;25:789–95.
  185. Lissoni P, Barni S, Ardizzoia A, et al. A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms. Cancer 1994;73:699–701.
  186. Lissoni P, Barni S, Ardizzoia A, et al. Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin. Oncology 1992;49:336–9.
  187. Lissoni P, Paolorossi F, Tancini G, et al. Is there a role for melatonin in the treatment of neoplastic cachexia? Eur J Cancer 1996;32A:1340–3.
  188. Lissoni P, Barni S, Tancini G, et al. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br J Cancer 1994;69:196–9.
  189. Lissoni P, Brivio F, Ardizzoia A, et al. Subcutaneous therapy with low-dose interlekin-2 plus the neurohormone melatonin in metastatic gastric cancer patients with low performance status. Tumori 1993;79:401–4.
  190. Aldeghi R, Lissoni P, Barni S, et al. Low-dose interlekin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma. Eur J Cancer 1994;30A:167–70.
  191. Lissoni P, Paolorossi F, Tancini G, et al. A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients. Br J Cancer 1996;74:1466–8.
  192. Lissoni P, Barni S, Mandalà, et al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer 1999;35:1688–92.
  193. Lissoni P, Brivio O, Brivio F, et al. Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma. J Pineal Res 1996;21:239–42.
  194. Neri B, Fiorelli C, Moroni F, et al. Modulation of human lymphoblastoid interferon activity by melatonin in metastatic renal cell carcinoma. Cancer 1994;73:315–9.
  195. Jolliet P, Simon N, Barr J, et al. Plasma coenzyme Q10 concentrations in breast cancer: prognosis and therapeutic consequences. Int J Clin Pharmacol Ther 1998;36:506–9.
  196. Lockwood K, Moesgaard S, Hanioka T, Folkers K. Apparent partial remission of breast cancer in “high risk” patients supplemented with nutritional antioxidants, essential fatty acids and CoQ10. Eighth International Symposium on the Biomedical and Clinical Aspects of Coenzyme Q10, Stockholm, Sweden, November, 1993.
  197. Lockwood K, Moesgaard S, Hanioka T, Folkers K. Apparent partial remission of breast cancer in ‘high risk’ patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Molec Aspects Med 1994;5(Suppl):S231–40.
  198. Lockwood K., Moesgaard S., Folkers K. Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochem Biophys Res Comm 1994;199:1504–8.
  199. Lockwood K., Moesgaard S., Yamamoto T., Folkers K. Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Comm 1995;212:172–7.
  200. Lockwood K, Moesgaard S, Hanioka T, Folkers K. Apparent partial remission of breast cancer in ‘high risk’ patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Molec Aspects Med 1994;5(Suppl):S231–40.
  201. Lockwood K, Moesgaard S, Hanioka T, Folkers K. Apparent partial remission of breast cancer in “high risk” patients supplemented with nutritional antioxidants, essential fatty acids and CoQ10. Eighth International Symposium on the Biomedical and Clinical Aspects of Coenzyme Q10, Stockholm, Sweden, November, 1993.
  202. Lockwood K, Moesgaard S, Hanioka T, Folkers K. Apparent partial remission of breast cancer in ‘high risk’ patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Molec Aspects Med 1994;5(Suppl):S231–40.
  203. Lockwood K., Moesgaard S., Folkers K. Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochem Biophys Res Comm 1994;199:1504–8.
  204. Lockwood K., Moesgaard S., Yamamoto T., Folkers K. Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Comm 1995;212:172–7.
  205. Michnovicz JJ, Bradlow HL. Altered estrogen metabolism and excretion in humans following consumption of indole-3-carbinol. Nutr Cancer 1991;16:59–66.
  206. Wattenberg LW, Loub WD. Inhibition of polycyclic aromatic hydrocarbon-induced neoplasia by naturally occurring indoles. Cancer Res 1978;38:1410–3.
  207. Cover CM, Hsieh SJ, Cram EJ, et al. Indole-3-carbinal and tamoxifen cooperate to arrest the cell cycle of MCF-7 breast cancer cells. Cancer Res 1999;59:1244–51.
  208. Riby JE, Chang GH, Firestone GL, Bjeldanes LF. Ligand-independent activation of estrogen receptor function by 3, 3’-diindolylmethane in human breast cancer cells. Biochem Pharmacol 2000;60:167–77.
  209. McDougal A, Sethi Gupta M, Ramamoorthy K, et al. Inhibition of carcinogen-induced rat mammary tumor growth and other estrogen-dependent responses by symmetrical dihalo-substituted analogs of diindolylmethane. Cancer Lett 2000;151:169–79.
  210. Walaszek Z, Szemraj J, Hanausek M, et al. D-glucaric acid content of various fruits and vegetables and cholesterol-lowering effects of dietary D-glucarate in the rat. Nutr Res 1996;16:673–81.
  211. Heerdt AS, Young CW, Borgen PI. Calcium glucarate as a chemopreventive agent in breast cancer. Isr J Med Sci 1995;31:101–5.
  212. Abou-Issa HM, Duruibe VA, Minton JP, et al. Putative metabolites derived from dietary combinations of calcium glucarate and N-(4-hydroxyphenyl)retinamide act synergistically to inhibit the induction of rat mammary tumors by 7,12-dimethylbenz[a]anthracene. Proc Natl Acad Sci 1988;85:4181–4.
  213. Shamsuddin AM. Metabolism and cellular functions of IP6:a a review. Anticancer Res 1999;19:3733–6.
  214. Dorant E, van der Brandt PA, Goldbohm RA. Allium vegetable consumption, garlic supplement intake and female breast carcinoma incidence. Br Cancer Res Treat 1995;33:163–70.
  215. Challier B, Perarnau JM, Viel JF. Garlic, onion and cereal fibre as protective factors for breast cancer: A French case-control study. Eur J Epidemiol 1998;14:737–47.
  216. Pedrinaci S, Algarra I, Garrido F. Protein-bound polysaccharide (PSK) induces cytotoxic activity in the NKL human natural killer cell line. Int J Clin Lab Res 1999;29:135–40.
  217. Kidd PM. The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev 2000;5:4–27 [review].
  218. Maehara Y, Moriguchi S, Sakaguchi Y, et al. Adjuvant chemotherapy enhances long-term survival of patients with advanced gastric cancer following curative resection. J Surg Oncol 1990;45:169–72.
  219. Kidd PM. The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev 2000;5:4–27 [review].
  220. Kaibara N, Soejima K, Nakamura T, et al. Postoperative long-term chemotherapy for advanced gastric cancer. Jpn J Surg 1976;6:54–9.
  221. Niimoto M, Hattori T, Tamada R, et al. Postoperative adjuvant immunochemotherapy with mitomycin C, futraful and PSK for gastric cancer. An analysis of data on 579 patients followed for five years. Jpn J Surg 1988;18:681–6.
  222. Nakazato H, Koike A, Saji S, et al. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 1994;343:1122–6.
  223. Ogoshi K, Satou H, Isono K, et al. Possible predictive markers of immunotherapy in esophageal cancer: retrospective analysis of a randomized study. Cancer Invest 1995;13:363–9.
  224. Hayakawa K, Mitsuhashi N, Saito Y, et al. Effect of Krestin (PSK) as adjuvant treatment on the prognosis after radical radiotherapy in patients with non-small cell lung cancer. Anticancer Res 1993;13:1815–20.
  225. Kondo M, Torisu M. Evaluation of an anticancer activity of a protein-bound polysaccharide PS-K (Krestin). In: Torisu M, Yoshida T (eds). Basic Mechanisms and Clinical Treatment of Tumor Metastasis. New York: Academic Press, 1985, 623–36.
  226. Toi M, Hattori T, Akagi M, et al. Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-year results from the Nishi-Nippon Group of the Adjuvant Chemoendorine Therapy for Breast Cancer Organization. Cancer 1992;70:2475–83.
  227. Iino Y, Yokoe T, Maemura M, et al. Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer. Anticancer Res 1995;15:2907–12.
  228. Morimoto T, Ogawa M, Orita K, et al. Postoperative adjuvant randomised trial comparing chemo-endocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemo-endocrine Therapy for Breast Cancer (ACETBC) of Japan. Eur J Cancer 1996;32A:235–42.
  229. Gvamichava AR, Khatiashvili TM, Khudzhadze RG, et al. First results of the use of Eleutherococcus in the combined treatment of breast carcinoma. Lek Sredestva Dal’nego Vostoka 1966;7:231–5 [in Russian].
  230. Kupin VI, Polevaia YeB, Sorokin AM. Stimulation of the immunological reactivity of cancer patients by Eleutherococcus extract. Vopr Onkol 1986;32:21–6 [in Russian].
  231. Gvamichava AR, Khatiashvili TM, Khudzhadze RG, et al. First results of the use of Eleutherococcus in the combined treatment of breast carcinoma. Lek Sredestva Dal’nego Vostoka 1966;7:231–5 [in Russian].
  232. Kupin VI, Polevaia YeB, Sorokin AM. Stimulation of the immunological reactivity of cancer patients by Eleutherococcus extract. Vopr Onkol 1986;32:21–6 [in Russian].
  233. Kleijnen J, Knipschild P. Mistletoe treatment for cancer. Review of controlled trials in humans. Phytomedicine 1994;1:255–60 [review].
  234. Dold U, Edler L, Mäurer HC, et al. Supplemental Cancer Therapy for Advanced Non-Small Cell Bronchial Carcinoma. Stuttgart: Georg Thieme Verlag, 1991.
  235. Douwes FR, Kalden M, Frank G, Holzhauer P. Treatment of advanced colorectal carcinomas. Deutsch Z Onkol 1988;21:63–7 [in German].
  236. Kjaer M. Mistletoe (Iscador) therapy in stage IV renal adenocarcinoma. Acta Oncol 1988;28:489–94.
  237. Steuer-Vogt MK, Bonkowsky V, Ambrosch P, et al. The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. Eur J Cancer 2001;37:23–31.
  238. Heiny BM. Adjuvant treatment with standardized mistletoe extract reduces leukopenia and improves the quality of life of patients with advanced carcinoma of the breast receiving palliative chemotherapy (VEC regimen). Krebsmedizin 1991:12:3–14 [in German].
  239. Nakachi K, Suemasu K, Suga K, et al. Influence of drinking green tea on breast cancer malignancy among Japanese patients. Jpn J Cancer Res 1998;89:254–61.
  240. Nakachi K, Suemasu K, Suga K, et al. Influence of drinking green tea on breast cancer malignancy among Japanese patients. Jpn J Cancer Res 1998;89:254–61.